MX337481B - Composiciones fotosensibilizantes. - Google Patents

Composiciones fotosensibilizantes.

Info

Publication number
MX337481B
MX337481B MX2012001953A MX2012001953A MX337481B MX 337481 B MX337481 B MX 337481B MX 2012001953 A MX2012001953 A MX 2012001953A MX 2012001953 A MX2012001953 A MX 2012001953A MX 337481 B MX337481 B MX 337481B
Authority
MX
Mexico
Prior art keywords
pharmaceutically acceptable
salts
water solubility
sulphonic acid
infusion
Prior art date
Application number
MX2012001953A
Other languages
English (en)
Other versions
MX2012001953A (es
Inventor
Jo Klaveness
Anders Hogset
Original Assignee
Pci Biotech As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pci Biotech As filed Critical Pci Biotech As
Publication of MX2012001953A publication Critical patent/MX2012001953A/es
Publication of MX337481B publication Critical patent/MX337481B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La invención se refiere a sales farmacéuticamente aceptables de agentes fotosensibilizantes, anfifílicos los cuales tienen una solubilidad en agua de por lo menos 0.5 mg/ml y a su uso en métodos para la interiorización fotoquímica. Estas sales se pueden formar a partir de una base farmacéuticamente aceptable, por ejemplo una amina orgánica tal como un aminoalcohol o a partir de un ácido farmacéuticamente aceptable, por ejemplo un ácido sulfónico o un derivado de ácido sulfónico. Debido a su solubilidad incrementada en agua, estas sales son particularmente adecuadas para el uso en la elaboración de preparaciones farmacéuticas parenterales, por ejemplo para el uso como soluciones para inyección o infusión.
MX2012001953A 2009-08-14 2010-08-16 Composiciones fotosensibilizantes. MX337481B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0914287.8A GB0914287D0 (en) 2009-08-14 2009-08-14 Compositions
PCT/GB2010/001547 WO2011018635A2 (en) 2009-08-14 2010-08-16 Photosensitizing compositions

Publications (2)

Publication Number Publication Date
MX2012001953A MX2012001953A (es) 2012-03-29
MX337481B true MX337481B (es) 2016-03-08

Family

ID=41171444

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012001953A MX337481B (es) 2009-08-14 2010-08-16 Composiciones fotosensibilizantes.

Country Status (23)

Country Link
US (1) US9026203B2 (es)
EP (1) EP2464384B1 (es)
JP (1) JP5946407B2 (es)
KR (1) KR101795362B1 (es)
CN (1) CN102648004B (es)
AU (1) AU2010283565B2 (es)
BR (1) BR112012003283B1 (es)
CA (1) CA2771021C (es)
DK (1) DK2464384T3 (es)
ES (1) ES2610143T3 (es)
GB (1) GB0914287D0 (es)
HR (1) HRP20161712T1 (es)
LT (1) LT2464384T (es)
ME (1) ME02616B (es)
MX (1) MX337481B (es)
NZ (1) NZ598380A (es)
PL (1) PL2464384T3 (es)
PT (1) PT2464384T (es)
RS (1) RS55530B1 (es)
RU (1) RU2574019C2 (es)
SG (1) SG178420A1 (es)
SI (1) SI2464384T1 (es)
WO (1) WO2011018635A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0914286D0 (en) * 2009-08-14 2009-09-30 Pci Biotech As Method
GB0914287D0 (en) 2009-08-14 2009-09-30 Pci Biotech As Compositions
WO2013009701A2 (en) 2011-07-08 2013-01-17 The University Of North Carolina At Chapel Hill Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders
GB201208548D0 (en) 2012-05-15 2012-06-27 Pci Biotech As Compound and method
EP2992000B1 (en) 2013-05-03 2020-07-08 The Regents of The University of California Cyclic di-nucleotide induction of type i interferon
WO2015028574A1 (en) * 2013-08-28 2015-03-05 Pci Biotech As Compound and method for vaccination and immunisation
JP6731404B2 (ja) * 2014-10-14 2020-07-29 ザ ユニバーシティ オブ シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 光線力学療法、ｘ線誘起光線力学療法、放射線療法、化学療法、免疫療法、及びこれらの任意の組み合わせのためのナノ粒子
US10806694B2 (en) 2014-10-14 2020-10-20 The University Of Chicago Nanoparticles for photodynamic therapy, X-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof
GB201503776D0 (en) 2015-03-05 2015-04-22 Pci Biotech As Compound and method
WO2017057784A1 (ko) * 2015-09-30 2017-04-06 (주)나노팜 여드름 피부개선을 위한 광민감성 물질을 함유한 건식다중캡슐형 조성물 및 그의 제조방법
WO2017201528A1 (en) 2016-05-20 2017-11-23 The University Of Chicago Nanoparticles for chemotherapy, targeted therapy, photodynamic therapy, immunotherapy, and any combination thereof
AU2017342086A1 (en) * 2016-10-14 2019-05-09 Pci Biotech As Treatment of cholangiocarcinoma with TPCS-2a induced photochemical internalisation of gemcitabine
WO2019028250A1 (en) 2017-08-02 2019-02-07 The University Of Chicago NOMOGENEOUS ORGANOMETALLIC ORGANOMETRIC ORGANOMETRIC LAYERS FOR X-RAY INDUCED PHOTODYNAMIC THERAPY, RADIOTHERAPY, RODIODYNAMIC THERAPY, CHEMOTHERAPY, IMMUNOTHERAPY, AND ANY COMBINATION THEREOF
CN107722075A (zh) * 2017-10-09 2018-02-23 大连理工大学 一类二氢卟吩葡萄糖苷类化合物及其制备方法与应用
GB201718631D0 (en) 2017-11-10 2017-12-27 Pci Biotech As Method
RU2720799C1 (ru) * 2019-07-03 2020-05-13 Федеральное государственное унитарное предприятие "Государственный научный центр "Научно-исследовательский институт органических полупродуктов и красителей" Способ определения фракционного состава сульфированного фталоцианина алюминия
RU2757936C1 (ru) * 2021-03-12 2021-10-25 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ прогнозирования риска развития хронической истинной экземы на основе молекулярно-генетических данных

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4582831A (en) * 1984-11-16 1986-04-15 Pfizer Inc. Anti-inflammatory polymorphic monoethanolamine salt of N-(2-pyridyl)-2-methyl-4-hydroxy-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide compound, composition, and method of use therefor
JPH0753861B2 (ja) * 1985-04-15 1995-06-07 味の素株式会社 紫外線吸収剤
US5284647A (en) 1988-03-18 1994-02-08 Schering Aktiengesellschaft Mesotetraphenylporphyrin complex compounds, process for their production and pharmaceutical agents containing them
US5292516A (en) 1990-05-01 1994-03-08 Mediventures, Inc. Body cavity drug delivery with thermoreversible gels containing polyoxyalkylene copolymers
US5346703A (en) 1990-08-07 1994-09-13 Mediventures, Inc. Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels
IT1254045B (it) * 1991-12-31 1995-09-06 Lifegroup Spa Derivati idrosolubili della biotina e relative composizioni terapeutiche
US5389681A (en) 1992-10-22 1995-02-14 Ciba-Geigy Corporation Parenteral solutions for diclofenac salts
FR2700543B1 (fr) * 1993-01-15 1995-03-17 Synthelabo Sels de dérivés de 4-pyrimidinone, leur préparation et leur application en thérapeutique.
DE4305523A1 (de) 1993-02-17 1994-08-18 Diagnostikforschung Inst Meso-Tetraphenylporphyrin-Komplexverbindungen, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Mittel
NO180167C (no) 1994-09-08 1997-02-26 Photocure As Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol
US6540981B2 (en) 1997-12-04 2003-04-01 Amersham Health As Light imaging contrast agents
US6992107B1 (en) 1995-03-10 2006-01-31 Photocure Asa Esters of 5-aminolevulinic acid and their use as photosensitizing compounds in photochemotherapy
EP0937478B1 (en) 1998-02-19 2003-08-27 Microflow Engineering SA Device and apparatus for intracavitary drug delivery during video-assisted surgery or other endoscopic procedures
GB9905911D0 (en) 1999-03-15 1999-05-05 Photocure As Method
US6398748B1 (en) 1999-03-16 2002-06-04 Robert B. Wilson Splint bandage and method
US6570013B2 (en) * 2000-02-16 2003-05-27 Pfizer Inc Salts of zopolrestat
BR0115795A (pt) 2000-11-29 2003-08-12 Pci Biotech As Métodos para introduzir uma molécula no citosol de uma célula, para o tratamento ou prevenção de uma doença, distúrbio ou infecção em um paciente, para estimular uma resposta imune, célula, e, uso de uma molécula de transferência e/ou um agente fotossensibilizante
DK1339862T3 (en) 2000-11-29 2014-02-17 Pci Biotech As PHOTO CHEMICAL INTERNALISATION VIRUS-MEDIATED MOLECULAR-DELIVERY INTO cytosol
GB0118251D0 (en) 2001-07-26 2001-09-19 Photocure Asa Method
GB0121023D0 (en) 2001-08-30 2001-10-24 Norwegian Radium Hospital Res Compound
NZ543565A (en) 2003-05-14 2008-12-24 Univ Sherbrooke Amphiphilic trisulfonated porphyrazines for photodynamic applications in medicine
GB0415263D0 (en) 2004-07-07 2004-08-11 Norwegian Radium Hospital Res Method
GB2420784A (en) 2004-11-25 2006-06-07 Pci Biotech As Phototherapeutic amphiphilic phthalocyanine-based compounds where 1 peripheral ring system is more hydrophilic & has more hydrophilic groups than the other 3
GB0514743D0 (en) * 2005-07-19 2005-08-24 Astrazeneca Ab Salt
WO2007021964A2 (en) 2005-08-11 2007-02-22 Massachusetts Institute Of Technology Intravesical drug delivery device and method
GB0605743D0 (en) * 2006-03-22 2006-05-03 Oxagen Ltd Salts with CRTH2 antagonist activity
JP2008095050A (ja) * 2006-10-16 2008-04-24 Hidetoshi Tsuchida アルブミン−金属ポルフィリン複合体および光増感剤
GB0811955D0 (en) 2008-06-30 2008-07-30 Pci Biotech As Method
GB0914287D0 (en) 2009-08-14 2009-09-30 Pci Biotech As Compositions
GB0914286D0 (en) * 2009-08-14 2009-09-30 Pci Biotech As Method

Also Published As

Publication number Publication date
LT2464384T (lt) 2017-04-10
KR20120094900A (ko) 2012-08-27
WO2011018635A3 (en) 2011-07-07
RU2012109559A (ru) 2013-09-20
BR112012003283A2 (pt) 2016-03-01
BR112012003283A8 (pt) 2016-05-17
US20120226217A1 (en) 2012-09-06
JP2013501769A (ja) 2013-01-17
RU2574019C2 (ru) 2016-01-27
KR101795362B1 (ko) 2017-11-08
PT2464384T (pt) 2017-01-12
CA2771021C (en) 2018-02-20
RS55530B1 (sr) 2017-05-31
EP2464384A2 (en) 2012-06-20
CA2771021A1 (en) 2011-02-17
ME02616B (me) 2017-06-20
GB0914287D0 (en) 2009-09-30
DK2464384T3 (en) 2017-01-23
MX2012001953A (es) 2012-03-29
AU2010283565A1 (en) 2012-03-15
WO2011018635A2 (en) 2011-02-17
HRP20161712T1 (hr) 2017-04-21
SI2464384T1 (sl) 2017-04-26
EP2464384B1 (en) 2016-10-12
ES2610143T3 (es) 2017-04-26
AU2010283565B2 (en) 2015-12-10
BR112012003283B1 (pt) 2020-06-16
CN102648004A (zh) 2012-08-22
JP5946407B2 (ja) 2016-07-06
NZ598380A (en) 2014-04-30
SG178420A1 (en) 2012-04-27
CN102648004B (zh) 2015-07-22
US9026203B2 (en) 2015-05-05
PL2464384T3 (pl) 2017-06-30

Similar Documents

Publication Publication Date Title
MX337481B (es) Composiciones fotosensibilizantes.
CY1122516T1 (el) Ετοιμες προς χρηση διατυπωσεις κετορολακης
UY30438A1 (es) Derivados n-sustituidos de 5-halo-4-[2-alquil-1-sustituidos-1h-imidazol-5-il]pirimidin-2-amina, composiciones-procesos para su preparacion y usos
AR077338A1 (es) Formulacion farmaceutica. procedimiento de preparacion. disolucion para perfusion.
EA201101672A1 (ru) Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина
EA200801998A1 (ru) ПИРИДИН[3,4-b]ПИРАЗИНОНЫ
WO2012054500A3 (en) Compositions for drug administration
DK2324008T3 (da) Diarylpyrazol som protein kinase inhibitorer
MX2010006799A (es) Benzofuropirimidinonas como inhibidores de la proteina cinasa.
NZ593110A (en) pteridinone derivatives as MODULATORS OF TOLL-LIKE RECEPTORS
MX2011012122A (es) Derivados de tiofeno.
UA94052C2 (uk) Похідні піридазину
TR201802944T4 (tr) İlaç olarak azai̇ndazol veya di̇azai̇ndazol türünün türevleri̇
SG10201407538WA (en) Intravenous formulations of neurokinin-1 antagonists
WO2008143240A1 (ja) 特定の有機酸を含有する経口製剤並びに経口製剤の溶出性及び化学的安定性の改善方法
IN2012DN00407A (es)
PE20120204A1 (es) Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas
AR068343A1 (es) Dipsipeptidos ciclicos
TW200637817A (en) 5-aminoindole derivatives
AR082049A1 (es) Formulaciones liquidas de rupatadina fumarato
EP2103610A4 (en) SALTS OF IMIDAZOLE-5-CARBOXYLIC ACID DERIVATIVES, METHOD OF MANUFACTURE AND USE THEREOF
WO2007097888A3 (en) Fluoroquinolone carboxylic acid salt compositions
UY30847A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales
TN2014000060A1 (en) Benzothiazolone compound
UA93365C2 (ru) Инъекционная форма диклофенака и его фармацевтически приемлемых солей (варианты) и способ его приготовления (варианты)

Legal Events

Date Code Title Description
FG Grant or registration